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The goal of this dissertation thesis is to fill in the gap in the literature regarding the 
influence of foreign stakeholders in the definition of the internationalization strategy 
for the health market, more specifically how they influence the definition of the 
internationalization strategy of a born global company. 
 
In order to answer the research question proposed we used qualitative research, 
specifically a case study approach. After presenting the relevant literature regarding 
this topic we collected primary and secondary data through interviews and archived 
internal and external documentation. 
 
Through the analyses of the information collected and based upon the theoretical 
literature, we can conclude that the government is the major stakeholder influencer 
with regards to the definition of the internationalization strategy of a born global in 
the health market. 
 




O propósito desta tese de mestrado é contribuir para o preenchimento da lacuna 
existente na literatura relativamente à influência dos stakeholders estrangeiros, do 
mercado da saúde, na definição da estratégia de internacionalização das empresas, 
mais especificamente como estes influenciam a definição da estratégia de 
internacionalização de uma empresa considerada uma born global. 
 
Para responder à research question proposta, utilizámos uma abordagem de estudo 
qualitativo, mais especificamente o método de case study. Após revisão da literatura 
relevante para este tópico, reunimos dados primários e secundários através de 
entrevistas e análise de documentação interna e externa. 
 
Através da análise da informação recolhida e tendo em conta a literatura teórica 
podemos concluir que os governos são o principal influenciador na definição de uma 
estratégia de internacionalização no mercado da saúde. 
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Since 1980, the world has been experienced a great evolution in terms of technology, 
telecommunications and transportation. The innovations in those fields reduced the 
difficulties faced with physical distance and people were able to communicate easier 
and faster in both face-to-face and non-face-to-face way. Companies also benefited 
from those innovations engaging in a process of increasing their involvement in 
foreign markets, through the adaptation of its operations, called internationalization 
(Johanson & Vahlne, 1977; Welch & Luostarinen, 1988; Calof & Beamish, 1995). 
 
Some firms became very successful by initiating their operations in foreign markets 
after establishing a strong presence in the domestic market, as expected. Whereas 
other firms were able to start operating successfully abroad before operating in the 
home market, which was not expected. Those firms that internationalize prior to home 
country establishment have been called International New Venture (McDougall & 
Oviatt, 1994) or born globals (Knight & Cavusgil, 1996).  
 
 “Born globals are emerging in substantial numbers worldwide, and likely reflect an 
emergent paradigm, with the potential to become a leading species in the ecosystem 
of international trade.” (Knight & Cavusgil, 2004, page 137). 
 
With the emergence of considered born global firms, it becomes increasingly 
important to do research about the phenomenon of this new type of companies.  
Despite the differences in terms of strategy, both born globals and traditional 
companies affect and are affected by some groups or individuals within the society. 
Literature proposed that those groups or individuals that can affect or are affected by 
the organization activities and achievements past, present, or future (Freeman, 1984; 
Clarkson, 1995) are considered stakeholders.  
 
Relevant literature tends to consider only the effect of stakeholders’ influence in 
traditional firms (Freeman & Reed, 1983; Cornell & Shapiro, 1987; Donaldson & 
Preston, 1995; Clarkson, 1995). Thus, there is a gap in the literature regarding the 
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influence of stakeholders in particular companies, which do not follow the traditional 
internationalization process, considered born globals. 
 
To fill in the gap mentioned, this thesis will focus our study on the 
internationalization strategy of a born global company. Additionally, we will focus 
specifically on the health sector, which because of its complexity presents more 
challenges regarding strategy definition and stakeholder identification and 
management. In this sense, our study will be guided by the following research 
question: 
 
How foreign stakeholders of the health sector influence the definition of the 
internationalization strategy of a born global? 
 
In terms of managerial relevance, the importance of the topic proposed relates to the 
fact that every company deals with stakeholders. The identification of key 
stakeholders and the management of their influence regarding, in particular, the 
definition of an appropriate strategy helps improve company overall performance and 
success. In this sense, through the study of the influence of foreign stakeholders in the 
definition of internationalization strategy, management can anticipate their impact and 
appropriately determine the best strategy in order to succeed. 
 
In order to answer the research question purposed and mentioned above, we adopted a 
qualitative research approach more specifically a case study. We then chose a 
company suitable to the analysis, with regards to the topic in study – Biosurfit, SA. 
This company is a Portuguese born global tech company that operates within the 
health market. 
 
This dissertation will be divided into five sections. The first section (literature 
review) aims to present relevant literature on the key topics of this thesis. We will 
start by the definition of internationalization followed by the introduction of the 
uppsala model, which aims to explain the process of internationalization. After in 
contradiction to the process explain by Johanson & Vahlne (1977) in the uppsala 
model, we will introduce the concept of born globals and their market selection and 
entry mode characteristics. The next subsection will regard the concept and the 
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influence of stakeholders upon all society including companies. Finally, as we aim to 
study specifically the health sector, the last subsection aims to describe the health 
sector and its specificities. After each subsection, we choose which definition and 
aspects will be used further in the dissertation.  
 
The second section (methodology) aims to describe the type of methodology used 
and the reasoning behind the choice of a qualitative research method more 
specifically a Case study. Also, in this section, we will present the primary and 
secondary data collected and the methods used in their analysis. 
 
In the third section (case study) we formulate the case study of Biosurfit, SA starting 
by the characterization of the company, its market and lastly the description and 
analysis of its internationalization strategy.  
 
Considering the data collected in the case study section, with regards to the relevant 
literature presented in the literature review section, we analyse and discuss the 
information gathered in the fourth section (findings). 
 
The last and fifth section (conclusion, limitations & further research) aims to present 
our main conclusions regarding the analysis made in the previous Findings section, as 
well as the limitations of this study and the suggestion of interesting topics for further 
research.  
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6. Literature Review 
 
This section aims to present the theoretical background used as a base of work for this 
dissertation. Through several papers, this chapter will introduce the key concepts that 
will be important further in the case study chapter.  The focus will be on the 
Internationalization concept and explanatory model, followed by the concept of born 
globals, the characterization of the health sector and finally the definition and 
influence of stakeholders. 
 
6.1 Internationalization  
 
As mentioned above, we will start by introducing the concept of internationalization, 




The concept of internationalization has been extensive researched and several 
definitions were proposed by renowned authors in academic papers published in 
important journals. 
Johanson & Vahlne (1977) define internationalization as a process in which 
companies, through a series of incremental decisions, gradually increase their 
involvement in foreign markets. In the same line of thought, Welch & Luostarinen 
(1988) also defined internationalization as a process in which a firm increases its 
involvement in international operations, depending upon six dimensions (operation 
method, sales objects, target markets, personnel, organizational structure and finance). 
According to Calof & Beamish (1995), internationalization is “the process of 
adapting firms’ operations (strategy, structure, resource, etc.) to international 
environments” (Calof & Beamish, 1995, page 116). 
 
Compiling the three definitions above, we can suggest that internationalization is, in 
fact, a process in which companies increase their presence in foreign markets through 
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a series of decisions, strategies and consequent adaptation of its operations to new 
business environments. 
 
In order to better understand the process of internationalization, authors have been 
trying to suggest a model that explains its characteristics. In the next subsection, we 
will define and examine the uppsala model, which aims to explain the characteristics 
of the internationalization process. 
 
6.1.2 Uppsala model 
 
In 1977, the authors Johanson & Vahlne alongside with providing a definition for the 
concept of internationalization created a model to explain all the steps of the 
internationalization process of firms. Called The Uppsala Model as it was created at 
Uppsala University, the model is based on two aspects, state and change, each having 
two variables each (market commitment and market knowledge, current activities and 
commitment decisions). All variables influence each other having a very dependent 
relationship as indicated in Appendix 1. In 2009, the authors revisited the model 
created in 1977 and changed what they considered the basic mechanism of 
internationalization. Whereas in 1977 the authors believed that the four variables that 
affected the internationalization process were the ones mentioned above, in 2009 they 
added two new concepts (knowledge opportunities and network position) to the basic 
structure of the model as we can see in Appendix 1. 
 
The Uppsala model assumes an incremental internationalization process based on the 
continuous acquisition and use of market knowledge as well as market commitment. 
The model emphasises that a firm starts only with home operations, with no 
involvement in foreign markets, but will tend to increase gradually throughout the 
years in incremental stages its presence abroad (Johanson & Vahlne, 1977; Johanson 





6.2 Born global 
 
This subsection aims to present the phenomenon called born globals starting with the 
origin of the concept followed by the specificities of born global firms captured by 
further research. 
 
6.2.1 Original concept 
 
In the 1990’s world witnessed the emergence of a new type of firms that did not 
follow an incremental, step by step internationalization process as described by 
Johanson & Vahln (1977). 
In this sense, McDougall & Oviatt (1994) provided a definition and a framework to 
explain the phenomenon of firms that internationalize from the beginning, for which 
the previous theory of the Uppsala Model does not apply. The authors created the 
concept of International New Venture (INV) as “a business organization that, from 
inception, seeks to derive significant competitive advantage from the use of resources 
and the sale of outputs in multiple countries” (McDougall & Oviatt, 1994, page 49). 
They argued that the world’s developments in terms of technology (international 
communication, transportation and lower fixed costs), economy (international funding 
and networks) and social conditions, lead to the possibility of this raising 
phenomenon. Besides, in order for INV to exist it is necessary to guarantee that the 
firm has control over unique resources, advantages in foreign locations, 
internationalization of some transactions and alternative governance structures 
(McDougall & Oviatt, 1994). 
 
Similarly, Knight & Cavusgil (1996) in their book “The Born global Firm: A 
Challenge to Traditional Internationalization Theory” characterize that type of firms 
with the term “born globals”. The authors go beyond the definition of INV and define 
born globals as firms characterized by: 
• Having been created by an entrepreneur or a group of entrepreneurs, emerging 
as a result of a development in technology; 
• Having a management team that considers the world the ideal marketplace for 
the firm since its foundation; 
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• Being considered small-medium size enterprises (SME’s) with average annual 
sales of less than 100 million dollars; 
• Selling products with substantial added value; 
• Exporting one or several products within at least two years of their foundation; 
• The fact that the quantity of product exported accounts for, at least, a quarter 
of the company’s total production. 
 
In the same line of thought, the authors also described some factors that they believe 
to influence and contribute to the emergence and success of born globals. With 
increasing global competition among big firms, small firms are forced to specialize 
and supply a global niche of customers (increasing importance of niche markets). 
Additionally, the constant development of new technologies allows SME’s to 
“streamline production in ways that make their products highly competitive in the 
global marketplace” (Knight & Cavusgil, 1996, page 21). Alongside with the 
developments in technology, the advances in communications technology enable born 
globals to communicate all around the world quicker and cheaper than in the past. The 
fourth factor influencing the success of born globals is the fact that SME’s are more 
flexible and adapt more quickly to situations, thus they respond better and faster to 
every market characteristic. Lastly, globalization enables companies to access to 
knowledge, technology, tools, institutions and networks all around the world 
facilitating cross-board activities. 
In 2004, the same authors revised the definition proposed in 1996 and provided the 
following definition of born globals: “business organizations that, from or near their 
founding, seek superior international business performance from the application of 
knowledge-based resources to the sale of outputs in multiple countries” (Knight & 
Cavusgil, 2004, page 124). 
 
Therefore, all authors state that born globals are firms that despite their relatively 
small size and lack of experience, beneficiate from a set of factors and characteristics 
such as management previous experience, becoming able to internationalize and 
export a significant part of their products successfully. We will adopt this definition 




6.2.2 The evolution of the concept 
 
Madsen & Servais (1997) published an article where they generate “propositions 
about the antecedents of as well as the necessary and sufficient conditions for the 
rise” (Madsen & Servais, 1997, page 1) of considered born global firms. Based on 
nine relevant case studies from firms originating from several different countries, the 
authors propose that the phenomenon of born globals is quite dependent of the degree 
of internationalization of the market and the size of the domestic market (higher 
degree of internationalization and smaller size of domestic market enable the 
appearance of born globals). Also, the bigger the domestic market the bigger tendency 
for born globals to appear only on high technology sectors. On the other hand, the 
entrepreneur who started the firm is proven to have a decisive role in its success. His 
previous experience defines the whole firm’s organization, strategy and processes as 
well as its geographic locations. In comparison to other internationalized firms, 
Madsen & Servais (1997) proposed that born globals specialize in niche markets 
relying strongly on partnerships to access effective Research and Development 
(R&D), distribution channels and networks. 
 
Another study, by Moen (2002), comparing French and Norwegian firms, shows that 
born globals, compared to other types of firms, present different characteristics. In 
terms of competitive advantages, global orientation, export strategy and market 
conditions, born globals were found to follow a niche focus strategy consistently, to 
use information technology actively, to score high on international responsiveness and 
to consider as especially important the market conditions as they find the export 
markets more attractive than the home markets (Moen, Ø. 2002). Despite the 
differences in value, the author concluded that different groups of firms tend to have 
similar characteristics. New and global, (born globals), tend to have similar 
characteristics to old and global firms, as well as new and local have similar 
characteristics to old and local firms (Moen, Ø. 2002). Additionally, the author did 
not find evidence that these firms follow the incremental step-by-step process of 
internationalization described by the traditional frameworks as Uppsala Model. 
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Years later, a third study was conducted with a dozen tech companies in Greater 
Cambridge Area Cluster. The authors saw that the perceived lack of opportunities in 
the domestic market and the need to serve a global multinational niche customer were 
key drivers for the internationalization of those companies. All born globals studied 
rely on distinctive technology and on the knowledge acquired from experienced 
managers and local networks (Kudina, Yip & Barkema, 2008). 
 
All studies found that born globals specialize in niche markets depending strongly on 
the entrepreneur’s previous experiences and partnerships with other firms. In this 
sense, the two studies emphasize some characteristics already presented by Knight & 
Cavusgil (1996) in the previous subsection. 
 
6.2.3 Market selection and entry mode 
 
When considering market selection and entry mode of born globals, we cannot 
consider traditional literature entirely once the uppsala model is not fully explanatory 
of the new phenomenon, and the born global theory was formulated in contradiction 
to it. 
 
Born globals tend to focus on a niche market, having to rely on the innovation aspect 
of its products. Furthermore, as these firms are relatively new, they strongly depend 
on other firms’ resources to grow and exploit foreign markets’ opportunities in the 
sense that networks are crucial to achieving international presence (Knight & 
Cavusgil 1996; Madsen & Servais, 1997; Moen, Ø. 2002).  Additionally, for born 
global, the physical distance of foreign markets is not a relevant aspect as in uppsala 
model. Relying on the previous experience of workers and guided by an opportunity-
seeking approach, born globals will choose the market to enter based on its niche 
opportunities and its networks and partnerships.  
 
Born globals as other firms influence and suffer from the influence of several groups 
of the society, which affects its operations. In the next subsection, we will analyse the 








In this subsection, we aim to not only present the concept of stakeholders and their 
different groups but also to explain their influence upon a company and its activities. 
 
6.3.1 Concept of stakeholders 
 
Society considered the term stockholders as the ones who have interest in the 
company to earn profits and which enable the company to exist as the ones who 
provide financing. In this sense, the neoclassic economic theory considers that 
companies only operate in order to make profits and satisfy the interests of 
stockholders (Freeman & Reed, 1983). According to academic references, the concept 
of stakeholder appeared for the first time in 1963, in an internal memorandum of the 
Stanford Research Institute as “those groups without whose support the organization 
would cease to exist” (Freeman & Reed, 1983, page 89). Despite being a very broad 
definition, it represents the beginning of the end of the neoclassic model and the birth 
of a socio-economic theory, which considers the importance of other participants 
apart from shareholders. 
 
Considering this definition by the authors Freeman & Reed (1983) proposed, in their 
article in 1983, two, more specific definitions for the same term: 
“Any identifiable group or individual who can affect the achievement of an 
organization’s objectives or who is affected by the achievement of an organization 
objectives.” (Freeman & Reed, 1983, page 91) 
“Any identifiable group or individual on which the organization is dependent for its 
continued survival.” (Freeman & Reed, 1983, page 91) 
Although different, both definitions complement each other. The first definition 
considers a reciprocal relation of influence between a firm and a specific group or 
individual which will ultimately lead to a dependence relation in terms of firm’ 
survival (second definition). In this sense, stakeholders are considered groups or 
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individuals that suffer influence and influence a firm, regarding the achievement of 
objectives, and become essential for a firm’ survival. 
  
In 1984, Freeman published the book considered essential for stakeholder literature 
called “Strategic management: A stakeholder approach”. In his book, the author 
gives a compiled definition of the concept, similar to the first definition given in 
1983, as “any group or individual who can affect or is affected by the achievement of 
the organization objectives” (Freeman, 1984, page 46). 
 
In 1991, Carroll published an article aiming to provide a framework to characterize 
firms’ CSR strategy in order for the management to join both the interests of the 
shareholders and the other stakeholders. In order to present its framework, the author 
considered stakeholders as a group or individual with influence in terms of the claim, 
stake or interest in the operations of an organization (Carroll, 1991). 
 
Besides, Clackson also gave a more complete definition of stakeholders, in 1995, 
since it considers a time factor. The author stated that stakeholders are “persons or 
groups that have, or claim, ownership, rights, or interests in a corporation and its 
activities, past, present, or future” (Clarkson, 1995, page 106) 
 
In fact, the first notion of the term stakeholder was broad and entirely organizational 
oriented but throughout time, the concept of stakeholders has consistently been 
associated with an exchange relationship between groups or individuals and 
organizations (Freeman & Reed, 1983; Carroll, 1991; Clarkson, 1995). The influence 
of a firm upon stakeholders and their influence upon a firm make them crucial for the 
achievement of a firm’s objectives and consequently its own survival. 
We have seen the evolution of the definition of the term stakeholder and will consider 
the definition given by Freeman (1984) with the time factor given by Clarkson 
(1995): stakeholders are any group or individual who can affect or is affected by the 
organization activities and achievements past, present, or future. Given this definition, 




6.3.2 Types and characteristics of stakeholders 
 
Considering the definition of stakeholders mentioned above (Freeman, 1984; 
Clarkson, 1995), we can separate them into two groups according to their dependence 
and importance for the company (Clarkson, 1995). First, we can consider as primary 
stakeholders, the groups or individuals who are affected or affect an organization and 
without whom it cannot continue its operations. The high level of dependence 
between primary stakeholders and the company makes it extremely important to fulfil 
their expectations. On the other hand, we can distinguish the secondary stakeholders 
as those groups or individuals who are affected or affect an organization and whom it 
does not need to survive. The low level of dependence between secondary 
stakeholders and the company make them capable to cause significant harm to the 
company but incapable them to end it (Clarkson, 1995). 
 
Additionally, we can distinguish four specific stakeholders’ attributes: Power, 
Legitimacy, Urgency and Salience (Mitchell, Agle & Wood, 1997). 
Stakeholders have power in the sense that they have or can acquire coercive, 
utilitarian or normative means in order to impose their preferences and desires to the 
company. Regarding legitimacy, “socially accepted and expected structures or 
behaviors” (Mitchell, Agle & Wood, 1997, page 866), stakeholders have desired, 
appropriate and expected behaviours within a certain installed system of norms, 
values and beliefs. Urgency is considered as the “degree to which stakeholder claims 
call for immediate attention” (Mitchell, Agle & Wood, 1997, page 867). It depends 
not only on the importance of the claim but also on the relationship between the 
company and the stakeholder. Finally, the attribute of salience relates with the former 
attributes described. It is perceived that the greater the stakeholder’s power, 
legitimacy and urgency are, the greater their salience. Thus, salience refers to the 
degree of which the company choose to give priority to claims of some stakeholders 
over the claims of other, competing, stakeholders (Mitchell, Agle & Wood, 1997; 
Harrison, & Freeman, 1999). 
 
The combination of the four stakeholders’ attributes, “create different types of 
stakeholders with different expected behavioral patterns regarding the firm” 
(Mitchell, Agle & Wood, 1997, page 863). In this sense, stakeholders’ influence upon 
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a company depends directly on their characteristics. The more power, legitimacy and 
urgency, the more salient and thus, the more influence will stakeholders have on the 
company and its management strategies. 
 
6.3.3 Firms’ strategy in response to stakeholders’ influence 
 
Carroll (1991) used terms as reactive, defensive, accommodative, and proactive to 
characterize a company’ strategy or posture towards its stakeholders according to 
their influence and how the company reacts. Based on the concepts introduced by 
Carroll (1991), Clarkson (1995), provided a performance scale in order to “measure 
and evaluate the level of responsibility that a company demonstrates in its 
management of stakeholder relationships and issues” (Clarkson, 1995, page 109) and 
the level of stakeholders’ satisfaction as follows: 
 
Source: Clarkson, 1995, page 109 
 
In accordance to this framework, the element of rating concerns the classification of a 
company’ strategy based on the way of dealing with the responsibility towards 
stakeholders issues (Posture or Strategy) and the results of the actions taken regarding 
those issues (Performance). Thus, stakeholders’ issues influence the way companies 
to deal with them and consequently, their strategies (Clarkson, 1995). 
 
Besides, although Clarkson (1995) characterized the strategy type of a company 
regarding stakeholder’s issues, it is important to also analyse the importance of 
managing stakeholders’ issues. Donaldson & Preston (1995) stated that stakeholders’ 
management affects the company in a three-level way, justified by three different 
theories: descriptive, instrumental, and normative theory. The descriptive theory is 
used to explain the relationships between stakeholders and the company observed in 
the external world. Hence, descriptive theory relates to the explanation of specific 
behaviours of the company in accordance to its characteristics, regarding the 
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conditions under which management consider certain groups as stakeholders 
(Donaldson & Preston, 1995; Mitchell, Agle & Wood, 1997). For instance, the nature 
of the firm, the corporate way of thinking about company’s interests and management 
decisions. The instrumental theory relates to the condition that certain practices 
carried out, lead to certain results will be obtained. This theory enables the 
identification of connections between stakeholders’ management and company 
results. Finally, the most internal way is the normative theory, which “presumes that 
managers and other agents act as if all stakeholders' interests have intrinsic value” 
(Donaldson & Preston, 1995, page 74). In this sense, the theory supports values and 
morals guidelines behind the management of the company with regards to its actions. 
 
Compiling descriptive accuracy, instrumental power, and normative validity of the 
three theories, the authors concluded that the three aspects of stakeholder theory 
complement each other. 
 
6.4 Health Sector 
 
The health sector presents distinct characteristics from other sectors of the economy. 
We will use this subsection to characterize the sector and its specificities.  
“Health care means health services provided by health professionals to patients to 
assess, maintain or restore their state of health, including the prescription, 
dispensation and provision of medicinal products and medical devices”1 (Directive 
2011/24/EU, article 3a, page 55) 
 
We can separate distinguish several businesses that belong to the health sector. We 
can consider, for example, businesses such as pharmaceutical companies (and 
pharmacies), health insurance companies and medical supply providers are part of the 
healthcare sector (The 10 Biggest Health Care Companies in the Fortune 5002). 
 
Regarding management literature, it is very difficult to find renowned academic 
articles regarding the overall characteristics of the health sector. In this sense, we will 
																																																								
1 From Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011, article 3a, page 55 
2 From http://fortune.com/2015/06/20/fortune-500-biggest-healthcare-companies/ 
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have to use medical academic articles and very specific management articles to try to 
describe this sector the best way we can. 
 
Besides, health care does not concern only the services for illnesses’ treatment but 
also services in terms of diagnosis, prevention, education, research and outreach 
(Omachonu & Einspruch, 2010). This sector deals with several different dimensions 
at the same time, which increases its complexity level. The necessity to manage the 
operations not only to face treatment of a wide spectrum of illnesses but also to 
provide the other services makes the health sector one of the most costly sectors. 
 
In the health care sector, quality and client satisfaction are very difficult to measure. 
For instance, quality can be divided into technical and functional quality in the sense 
that “Technical health care quality (THQ) can be defined primarily as the degree of 
adherence to established technical norms and procedures, whereas functional health 
care quality (FHQ) is the manner in which the health care services are delivered” 
(Ward, Rolland & Patterson, 2005, page 362). The authors realized that, through a 
study with outpatients’ surveys, the four dimensions of Interaction & 
Communications, Access, Tangibles and Outcome are the greater influencers in 
patient-perceived quality. In this sector, interpersonal interactions are as valued as the 
technology and physical resources (Zhang, et al. 2017) unlike in most of the other 
sectors. 
 
In order to cope with the fast pace of the health sector, new technology is always 
being developed. Health care innovation can be found either through product 
innovation (e.g. new drug) or through process innovation (e.g. new surgery 
technique). According to the authors Omachonu & Einspruch (2010) “Healthcare 
innovation can be defined as the introduction of a new concept, idea, service, process, 
or product aimed at improving treatment, diagnosis, education, outreach, prevention 
and research, and with the long term goals of improving quality, safety, outcomes, 
efficiency and costs.” (Omachonu & Einspruch, 2010, page 5). The constant search 




Regarding the government involvement, the authors Thuohy & Glied (2011) proposed 
that governments intervene in the health sector in four different ways. First, 
governments are distributors of health care in the sense that, to maintain equity among 
citizens, they implement policies to redistribute resources. Health care resources are 
also encompassed in the redistributive policies adopted.  
 
The second way is related to information gaps. Despite being a sector that provides 
services, the information gap between professionals and patients leads them to 
“dependent on the advice of medical experts to tell them what and how much health 
care to “consume” (which) means that patients do not purchase services in a 
conventional sense” (European Commission- Health & Consumer Protection 
Directorate-General, 2001, page 7). In fact, governments try to guarantee the minimal 
quality standards and patient safety by product and procedure regulations as well as 
regulations of health care related professions (Thuohy & Glied, 2011). 
 
Thirdly, governments make a direct and indirect investment in the health care sector 
through for example the construction and/or improvement of health care facilities, the 
education of health care professionals, the sponsoring of health care related R&D 
activities and the concession of grants (Thuohy & Glied, 2011).  
 
Finally, the authors considered that governments are also involved in this sector 
through “the regulation and taxation of goods and behaviors that generate 
externalities” (Thuohy & Glied, 2011, page 61). Extra taxes can be applied to the sale 
of cigarette packages in order to avoid their consumption and minimize negative 
externalities such as respiratory diseases. 
 
In fact, the health sector is one of the most regulated sectors of the economy. 
Although each country has its own specific health sector regulations, there are some 
common directives for health products, services and patients along groups such as the 
EU. For instance, products need to be CE marked in order to be able to be 
commercialized within the EU territory and medical products for human and 




As the health sector can be divided into primary, secondary and tertiary health care 
we will analyse each element separately. 
 
Primary health care is considered the core of the health care sector that represents the 
first point of contact between service users (patients) and health care professionals. 
This stage involves a wide scope of health care services performed by general health 
care professionals not only to treat illnesses but also to improve the overall health of 
all citizens. 
The Alma-Ata Declaration established that primary health care should rely on five 
essential pillars namely universality, quality, equity, efficiency and sustainability 
(World Health Organization, 2003). Universality regards to the fact that every person 
should have access to the same set of primary health care services and quality to the 
fact that “primary health care services should be socially and culturally acceptable 
and in line with standards of scientific and clinical practice, and at a level that will be 
perceived as adequate by beneficiaries” (World Health Organization, 2003, page 1). 
The pillar of equity is based on the fact that everybody should have access to primary 
care services independently form their willingness and capacity to pay for them. In 
addition, sustainability and efficiency relate to the fact that there should be enough 
resources to provide primary health care service in the short and long run and that 
those resources should be managed in a cost-efficient way, respectively.  Primary 
health care professionals refer patients to secondary and tertiary health care 
professionals according to the characteristics of the pathology presented. 
 
The next level is the secondary health care that relates to the treatment of non-very 
complex illnesses by more specialized health care professionals. Secondary health 
care professionals often specialize either in a specific system of the body, or a specific 
illness (e.g. dermatologists). Despite their degree of specialization, secondary health 
care professional need to refer the patient to tertiary health care professionals for the 
treatment of some illnesses. In this sense, tertiary health care represents the treatment, 
with specialized equipment, by specialist professional, of serious illnesses (e.g. 
cardiac surgery). 
 
The health sector is thus, one of the more complex sectors of the economy. Not only 
in the sense that involves all the uncertainty concerning life and strong personal 
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interaction but also in the sense that implies high costs and a large number of 
regulations. 
 
In the next section, we will describe the methodology used in this dissertation and the 





This chapter aims to present and explain the type of methodology and procedures 
used for data collection and analysis that made possible the chapters of findings and 
conclusion.  
 
7.1 Qualitative methodology  
 
In order to answer the research question mentioned previously, the methodology used 
was qualitative research.  
According to Mack et al. (2005), qualitative research is a type of research which aims 
to answer a question and solve a research problem through predefined procedures and 
evidence collected, in order to produce findings that were not only already determined 
but that also go beyond the boundaries of the specific study. Considering the topic of 
this dissertation, the most appropriate research approach is qualitative research since 
it is a dynamic phenomenon that can hardly be explained by quantitative methods. 
 
Furthermore, Yin (2009) developed a framework in order to provide a way for 
researchers to select the best qualitative research method, based on three conditions. 
First of all, it is important to consider the type of research question posed, the extent 
to which the researcher can control the behavioural events and, finally, the preference 
for focusing on current events as opposed to historical events. After defining the three 
conditions mentioned above, the author proposes five possible research strategies as 
shown in Appendix 3. Given the research question defined in this dissertation, the fact 
that we do not have control of the behavioural situations and the focus on current 
events rather than historical ones, Yin’s Framework suggests that the most 
appropriate qualitative research method is a Case study. According to Yin (2009), a 
case study is “an empirical inquiry that investigates a contemporary phenomenon 
within its real-life context” (Yin, 2009, page 13). 
 
Hence, in this dissertation, we will use the Case study research method. We chose 
Biosurfit, SA, as the company suitable to be the subject of a case study, as it is a 
portuguese company which stated by commercializing its products in foreign markets 
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instead of in the Portuguese market (born global), and operates in the health care 
sector, selling a fully automated diagnostics machine to perform blood tests. The 
company is influenced strongly by stakeholders of foreign markets in the definition of 
its internationalization strategy. 
 
7.2 Data collection  
 
Data can be separated into primary data, which is the data collected by the researcher 
himself for the first time and secondary data, which is the data collected by a third 
person and later used by the researcher. In fact, each Case study can have its data 
collection made by several methods including archives, interviews, questionnaires and 
observation, which can provide also quantitative and qualitative data (Eisenhardt, 
1989). Besides, according to Yin (2009), the more sources of data collection used, the 
more convincing and assertive are the findings. In this sense, it is important to use at 
least one type of data triangulation: investigator, theory, and method or data source 
triangulation in order to mitigate possible bias of information. 
 
In this dissertation, in order to use Data Source and Method Triangulation, we 
collected primary data through meetings and interviews, with more than one key 
informant, and secondary data through archived records and documentation. We 
conducted three interviews with different company employees, in order to not only 
triangulate data and cross-validate the information given, but also to avoid 
information bias. The interviews were conducted with Dr Joao Fonseca, Dr Daniel 
Neves, Dr Luis Lopes and Dra Sofia Ribeiro as we can see in the figure below. 
 
The first interview with the CEO was used to discuss broad topics such as an overall 
view of the company and its history. Besides we discussed, as well, the 
internationalization process and the arrangements for further interviews and 
information access. The second interview, with Dr Daniel Neves, enabled to go 
deeper into the characterization of the company, its internationalization process and 
Interviewee Position Date Time
Dr João Fonseca CEO 03.11.2017 30 min







further plans for expansion. In addition, we discussed the importance of stakeholders 
in market selection and entry mode of Biosurfit. Lastly, the topics covered in the joint 
interview with Dra Sofia Ribeiro and Dr Luis Lopes were the path of 
internationalization, the importance of international fairs and of stakeholders in 
market selection and entry mode of the company, the barriers and difficulties of 
expansion and the next steps of internationalization (See Appendix 4). 
 
The secondary data can be divided into internal documentation, which was given by 
the company itself and external documentation, which was collected from other 
sources outside the organization. The internal documentation collected ranges from 
Company’s internal reports to shareholders’ presentations whereas external 
documentation was mainly collected from websites. (See Appendix 5) 
 
7.3 Data analysis 
 
For the data analysis, we used a coding approach, (see Appendix 6), where we 
separated the data collected into groups according to key concepts. Additionally, the 
process of coding the data into a table allowed us to preserve information in the actual 
terms used by the key informants’ interviews. For example, we coded as market the 
following quote of Dr Daniel Neves “Not in terms of medical decisions but in terms of 
personal preferences (…) patients are willing or not to pay more for a quick result 
and not having to go to the doctors’ office a second time” because it concerns the 
patients’ preferences which is one of the aspects considered in the firms’ approach to 
market selection of a foreign market. 
 
All data fostered a deeper understanding of the company, its internationalization 
process and the way foreign stakeholders influence the definition of the company’s 
internationalization strategy. We were able to use the data collected in order to 
present a case study (chapter 8) and consequently the findings and conclusion sections 
(chapter 9 and 10). 
 
The Case study section will be divided into three subsections. The first subsection 
aims to present an overall view of the company subject to study, followed by a view 
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of the market in which it operates (overall health market and PoC market). Finally, we 
will describe and analyse the internationalization process and strategy used and 
consequently its results. 
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8. Case study 
 
This section aims to present the Case study of this dissertation. We will start by 
describing the company, its market and lastly its internationalization strategy and the 
results of the approach used. 
 
8.1 The Company 
 
This subsection aims to present the company Biosurfit as the firm subject to the Case 
study. 
 
After going to the hospital with his sick three-year-old son, Dr João Fonseca 
considered it unacceptable to have to wait several days for the results of the blood 
tests to define the treatment suitable to the child’s illness. In this sense, the current 
CEO started its own company to address this health system problem.  
Biosurfit, SA was founded in Lisbon, Portugal, in 2006 by Dr João Fonseca to 
develop a fast and reliable technology for in-vitro diagnostic testing.  
“At biosurfit we are working to shape the future of in-vitro diagnostic testing. 
We want health providers to have all the necessary information to make the best 
possible diagnostic and treatment decision when they are with their patients.”3 
With a very experienced board composed by Dr João Fonseca (CEO), Dr Nuno Reis 
(COO), Dr Ian Gilham (Chairman since 2013) and Dr Daniel Neves (CMO and CFO 
since 2009), the company has been systematically growing through the years. 
Nowadays, the Biosurfit counts with more than 100 employees in its headquarters and 
semi-automated manufacturing line located both in the city of Lisbon. 
 
In order to perform a blood test, with the current conventional system, patients are 
normally referred to specialized blood-draw clinics, having to wait for several days 
until receiving the tests result. Besides, from the point of view of the institutions, it 
can be necessary to use several equipment in order to do a unique blood test which 
require different storage place, technicians training, maintenance requirements, power 
																																																								
3 From http://biosurfit.com/company/ 
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supply, quality control and procedures, printers, sample collection material, logistics 
and ordering and finally the connection between results. 
Biosurfit commercializes a fully automated diagnostics machine, designed to deliver 
blood analysis information in minutes under the brand spinit®. This machine is a 
point-of-care diagnostic system capable of performing the three major blood tests 
(haematology, immunoassays and clinical chemistry) on the same instrument. In order 
to enable the performance of specific tests, the company also sells the disposable 
discs on CD/DVD format (spinit® CRP, spinit® BC and spinit® HbA1c). Also, 
depending on the type of test, the results are shown on the screen after a maximum of 
ten minutes with the same accuracy as a laboratory test.  
 
Figure 1 - spinit® diagnostics machine and disposable discs (Source: Shareholder 
presentation, 2017) 
 
It is essential for any company operating within the health sector, in the EU, to have 
its products CE marked and ISO 9001 and ISO 13485 certifications before being 
allowed to operate. In 2009, the company received both ISO certifications and, 
throughout the years, all tests launched by Biosurfit and the machine itself are CE 
marked, which means they comply with the essential requirements of European 
health, safety and environmental protection legislation and can legally be placed in 
the market, ensuring the free movement of the product within EFTA and EU market. 
Furthermore, the company achieved IFCC (International Federation of Clinical 
Chemistry and Laboratory Medicine) certification and NGSP (National 
Glycohemoglobin Standardization Program) certification, acknowledging the 
compliance with international laboratory standards. 
 
Throughout the years, Biosurfit has received several awards namely Biggest 
Healthcare Innovation Award, in World Innovation Summit 2011, Barcelona and 
“Start-Up of the year” award by Portugal Ventures in 2013 and in 2015 and the 
distinction of “Born from Knowledge” at the National Meeting of Innovation 
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COTEC-ANI in 2017. Besides, the company has also been awarded grants from the 
European Commission, IAPMEI and Horizon 2020. 
 
8.2 The market 
 
In order to analyse the market for Biosurfit’s products, it is important to first 
understand the global health market in Europe for the past years and then focus on the 
target market of the company. 
 
According to data by The World Bank, the public health expenditure as a percentage 
of the GDP, for the European Union, has increased significantly since 2006 to 2014. 
Statistics show that, in 2006, the EU countries registered a public health expenditure 
of 7.09%4 of GDP compared to 7.82%4 in 2014. Considering the increase of European 
Union’s total GDP from 15.3895 Trillion USD to 18.5885 Trillion USD in 2014, we 
can see that the amount registered for health expenditures increased 3.199 Trillion 
USD since 2006. Additionally, Eurostat shows that in the majority of EU members, 
hospitals are the main providers where health care expenditures range from 29.5%6 of 
the total health care expenditures in Germany to 47.9%6 in Estonia in 2014. 
Additionally, both Eurostat and The World Bank, state that direct out-of-pocket 
spending (health services directly paid by the patient) has grown more rapidly than 
public spending.  
 
There are several factors contributing to the increase of health care expenditures 
showed by the statistics. First of all, the growth of world’s population, the increase of 
life expectancy, the better access to health care and the increase of the number of 
lifestyle-related diseases, contribute to the increase of the number of health care 
system users and thus, to the necessity of a greater amount of health care provider 
institutions. Besides, with the constant evolution of R&D, there are more treatments, 
exams and techniques employed in the health care system which can ultimately lead 
to the growth of health care expenditures. 
 
																																																								
4 From https://data.worldbank.org/indicator/SH.XPD.PUBL.ZS?locations=EU&view=chart 




Biosurfit does not intend to serve the whole health care market, instead, the company 
focus its products on primary health care, more specifically on the Point of Care 
Diagnostics Market (PoC market). The global market value for PoC diagnostics 
(accounting for self-testing and professional PoC segments) was 177 billion USD in 
2014 and spinit® target segment, considering doctors’ offices and hospitals (primary 
care), accounted for 4.76 billion USD (28% of the global market).  
 
Regarding competition, Roche, Alere, Abbott, and Siemens are considered the largest 
companies in point of care diagnostics in terms of revenues. Despite the existence of 
several competitor companies that commercialize similar systems to spinit®, none of 
them is able to perform the same number of different tests and none of them is 
commercialized at the same low price range. 
 
8.3 Internationalization process 
 
Biosurfit started by commercializing its products outside its country of origin which 
means, the company started exporting before domestic market selling. First, it is 
important to analyse the process itself, considering the strategy used and then the 
outcomes. 
 
8.3.1 Process of Internationalization 
 
After all the approvals needed, in 2013, Biosurfit was ready to commercialize its 
product abroad. The company started by (and continues) attending several 
international health care fairs like MEDICA (“The world's leading trade fair for the 
medical industry”8) in order to expand its network and acquire further knowledge.  
 
“At international fairs, we (Biosurfit) talk to many people from many different 
countries and many different types of companies. (…) We end up being able to extract 
some valuable information about markets which facilitates the choice of a market to 
enter in and furthermore, we end up expanding our already existing network. (…) 
																																																								
7 From Https://www.kaloramainformation.com/Point-Care-POC-10616559/ 
8 From https://www.medica-tradefair.com/ 
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Thus, international fairs are, in fact, a big investment made by us (Biosurfit) in terms 
of internationalization”9 
 
Regarding the market presence of the company, Biosurfit adopted a special approach 
in order to choose a new market to enter into. The approach used considers four key 
principles as mentioned below: 
 
• PoC market - National Health care system  
• Reimbursement policy 
• Physicians preferences  
• Patient preferences  
 
In order to evaluate the PoC market, it is important to consider if the National Health 
care System is centralized or decentralized. Thus, the important aspect is not the size 
of the market per se but the way it is organized. In a decentralized system, a patient 
needs to go first to a doctors’ office and then, only if referenced, to the hospital. 
Whereas in a centralized system, a patient can go directly to the hospital. As hospitals 
have a central laboratory to support them, the more decentralized the National Health 
care System the greater likelihood for a doctors’ office to acquire spinit® products.  
 
Additionally, the reimbursement policy in each country affects the possible success of 
the commercialization of spinit® products. The National Health care Systems and 
insurance companies reimburse certain medical expenses which can cover or not 
Biosurfit’s tests. In this sense, the reimbursement policy affects the prices being that 
for doctors the reimbursement represents receiving the price asked and for the patient 
represents paying less.  
 
Thirdly, the doctors’ preferences in terms of treatments, products and decision 
making. In different countries, doctors’ can prefer for example traditional blood 
testing over the testing solution provided by Biosurfit. Besides, in order to decide the 
same treatment, different doctors can prefer the analysis of different types of test. 
 
																																																								
9 From the interview with Dra Sofia Ribeiro on 06.12.2017 
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Moreover, the last aspect considered by Biosurfit is patient’s preferences in the 
country. On one hand, populations can really dislike the traditional method of taking 
blood or can feel indifferent about it. On the other hand, patients can or not be willing 
to pay an extra for the fact that they only need one, longer appointment instead of one 
to request the blood tests and one to show the blood tests’ results to the doctor. 
 
Considering the four-key-aspect approach, Biosurfit defined Belgium, Netherlands 
and Luxemburg as the most attractive countries to enter in since they easily accept 
innovations of health care, have a decentralized National Health care Systems and a 
reimbursement system well defined. 
 
Additionally, the company defined that, considering its characteristics and the target 
market, the best entry mode would be only through distribution agreements. Biosurfit 
is a relatively small company with limited resources, and the fastest and most efficient 
way to guarantee the commercialization of spinit® products in doctors’ offices and 
primary care institutions in foreign markets, is to partner with a local distributor and 
sign distribution agreements. In order to choose the most appropriate partner, the 
company evaluates not only the distributors’ capacity of investment (there is a 
requirement of an initial investment in spinit® products) but also their offer of other 
products (the distributor cannot sell two or more similar products to spinit®).  
 
Considering the BENELUX region and the entry mode, Biosurfit took advantage of 
the fact that the major competitor in the region was bought and thus, the local 
distributor for the Netherlands would no longer be able to sell the product. In fact, in 
2013, Biosurfit signed its first distribution agreement and in 2014, the Netherlands 
became the first country to commercialize spinit® products. After a while, the 
company entered into negotiation with a company, created by former employees of 
the competitor, in order to sign a distribution agreement for Norway, Finland, Sweden 
and Denmark. 
 
The entrance in the Nordic group was followed by the signature of distribution 
agreements for UK, Austria, EU Eastern Countries (e.g. Slovakia, Croatia), Romania 
and finally Swiss.  
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After the success in European countries, the company decided to enter the Middle 
East namely United Arab Emirates, Kuwait, Qatar, and Saudi Arabia. 
The internationalization strategy for the Middle Eastern countries was very similar to 
the one followed in order to enter the European markets. However, Biosurfit had to 
adapt to certain cultural characteristics of those Arab societies. For instance, face-to-
face communication is much more valued in Arab culture than in Europe which 
forced the company to regularly send Dr Luis Lopes to those countries in order to 
establish a personal relationship with all parts of interest. 
 
“Arab population like to meet and deal with people face-to-face (...) and we saw more 
progress and achieved more results after visiting the country than through months of 
non-face-to-face negotiation.”10 
 
The relationship with local companies that can become Biosurfit’s local distributors is 
thus, very important for the company. Nowadays, Axon Lab AG, an independent 
European distributor, focusing on medical diagnostics, life science and software 
solutions for the health care sector is one of the major partners of the company. 
Through the establishment of distribution agreements, Axonlab has the rights to 
promote, market, and sell the spinit® instrument and associated discs to hospitals, 
doctors, clinics, private laboratories and research institutions in all EU Easter 
Countries where Biosurfit is currently present. 
 
8.3.2 Results of the internationalization process 
 
Following the strategy described above, Biosurfit has, currently, a commercial 
presence and sells its products in over twenty European countries and four Middle 
Eastern countries, with plans to expand to the United States and Asia. 
																																																								
10 From the interview with Dr Luis Lopes on 06.12.2017 
	 36	
Figure 2 – Biosurfit’s presence worldwide (Source: adapted from internal presentation 2017) 
 
Since 2006, the company has substantially increased its overall operations not only in 
terms of sales but also in terms of international presence. Nowadays, Biosurfit sells its 
products in European countries such as The Netherlands, England, Norway and 
Switzerland and in Middle Eastern countries such as Qatar and UAE. 
 
Regarding sales, Biosurfit’s overall sale revenue increased over sixteen times from 
56.070 Euros in 2014 to 940.147 Euros in October 2017 (see Appendix 7). 
Considering sales of individual products, the company was only able to retrieve 
information until 2016. spinit® machines represent the core of the company’s 
revenues in comparison to the dispensable discs, 306.019 Euros comparing to 68.081 
Euros in 2016. Over a total number of 640 machines in the market by October 2017, 
Austria and Czech Republic are shown to be two of the most important markets with a 
total of 299 machines commercialized. Nonetheless, the market of the Netherlands is 
also very significant as it alone accounts for 183 equipments, representing 29% of the 
total number of spinit® machines around the world (see Appendix 8).  
 
The expansion and increased volume of transactions lead to the need for a greater 
production capacity and more workforce. In this sense, the number of employees as 
been increasing throughout the years, from four in 2006 to seventy-seven in 2014, and 
currently, in 2017, to 122 employees. Besides, Biosurfit initiated and finished the 
construction of a new 4.500 m2 semi-automated production facility in Azambuja, with 






This chapter aims to answer the research question proposed of “How foreign 
stakeholders of the health market influence the definition of the internationalization 
strategy of a born global?” based on the information gathered in the case study 
section (chapter 8) and the frameworks in the literature review section (chapter 6). 
The first step was to identify key stakeholders of the company, based on the four key 
approach followed in other to do market selection. We will perform our analysis 
separating different stakeholders, such as governments and customers, based on their 
higher degree of influence upon a company and its internationalization strategy.  
 
9.1 Governments’ influence 
 
The nature of the market makes it imperative to have government participation in all 
activities, trough not only the construction of medical facilities but also the 
establishment of a national health care systems and regulations. In this sense, 
governments are one of the most influent stakeholders of this market. 
 
In this regard, Biosurfit was greatly influenced by the market conditions created by 
government actions.  
In one hand the company needed to get specific certifications in order to comply with 
certain directives and being able to commercialize its products in each country and 
across the EU. Those certifications delay the entrance of the company in the market as 
they need to be prior obtained to allow the commercialization of the products. 
Besides, the company needs to incur certain expenses in order to obtain those 
certifications. As a result, the necessity to comply with the regulations not only lead 
Biosurfit to start developing its products in 2006 but to start selling them only in 2014 
but also to spend extra money. A market with more specific regulations required in 
order for a company to enter becomes less attractive when considered in the market 
selection as imply many certifications and extra-expenses. 
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"The minimum requirements in order for us to sell our products are CE marking, 
which allows us to sell within the EU; ISO 9001 and ISO 13485."11 
 
On the other hand, as we have seen, the National Health care System is very 
important to Biosurfit. Governments are responsible for the way the health care 
system is organized and the interconnection of health care facilities. The level of 
centralization of the system impacts both market selection and entry mode of a 
company. On one hand, it influences the possibility to reach a significant number of 
private doctors’ offices and primary care units in the sense that great decentralization 
results in a great possibility to reach the target market. On the other hand, the 
necessity to satisfy a decentralized market requires the definition of an appropriate 
way to enter the market and reach every customer. In this sense, a country with a 
decentralized health care system is more attractive to Biosurfit than a country with a 
centralized health care system, since, with the right entry mode, it is more probable to 
reach a greater number of target customers. 
 
"If the National Healthcare System encourages the realization of blood tests near the 
patient, it becomes attractive to us."12 
 
On top of that, the reimbursement policy defined by the government is also very 
important for market selection as it impacts the prices that can be practised by the 
target market and thus, the acceptance level and the number of Biosurfit’s products 
commercialized. The better established and the more reimbursement available for 
tests offered by Biosurfit, the more attractive becomes the market. The greater the 
reimbursement policy for specific tests, the higher the prices that doctors can practice 
without losing patients since they will get the refund. If patients have support from the 
system they will not be averse to go to a doctor’s office and perform the required 
analysis even if they have to pay more for the consultation or the exams. The 
reimbursement policy will, thus, ultimately influence doctors to acquire Biosurfit’s 




11 From the interview with Dr Daniel Neves on 06.12.2017 
12 From the interview with Dr Daniel Neves on 06.12.2017 
	 39	
“Other important factor is the reimbursement policy which can turn attractive or not 
to commercialization of our products in that country."13 
 
Additionally, it is important to consider the type of political system in each country. A 
country with a closed political system is less likely to accept foreign products thus, it 
will not be considered as an option from market selection. Besides, a system that 
strongly promotes internal R&D will tend to impose strict regulations regarding 
foreign technology. On the other hand, a government that searches for innovation, 
even if it comes from foreign countries, will tend to influence market conditions in 
order to increase the country’s level of attractiveness for technology innovations. 
 
In this sense, the governments’ influence upon market conditions, through regulations 
and established policies, leads the company to choose or not a country in the market 
selection part of the internationalization strategy. 
 
9.2 Customers’ influence 
 
As we have seen, customers are considered stakeholders as they influence and are 
influenced by the company’s actions and achievements past, present and future. In 
this sense, born global customers are not an exception. Biosurfit’s customers are not 
only its distributors but also the patients and doctors that use the spinit® products. 
 
The distributors are crucial for the company as Biosurfit is a born global with limited 
resources. The company does not have enough capacity to self-distribute products in 
each country thus, the existence of experienced and well-positioned distributors, 
which comply with the requirements of the company, is the only way to expand to 
foreign markets. Local distributors that already have networks, knowledge and 
operations set up in place represent a foreign advantage for the company as it can 
beneficiate from those partnerships, not having to carry all functions each time they 
enter a different country. Without the signature of agreements with local established 
distributors, it would be impossible to sell spinit® products thus, Biosurfit is only able 
to be present in more than twenty countries because of the distribution agreements 
																																																								
13 From the interview with Dra Sofia Ribeiro on 06.12.2017 
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signed with more than five different distributors. In this sense, distributors become 
key stakeholders in the internationalization of Biosurfit since the best entry mode to 
reach the greatest number of customers is to lean on local partnerships which, 
consequently, enable products’ sales. 
 
"We have decided to have an indirect channel of distribution, we will not sell directly 
in each country as our target is GP offices and primary care units."14 
 
Likewise, patients and doctors are also very important for Biosurfit as they affect 
international responsiveness. As a born global, the company specializes in a niche 
market, being crucial to have a significant degree of approval in order to enter a 
specific foreign market. Citizens’ preferences in each country define the extent of 
approval and use of the products in the sense that established culture influences 
people’s willingness to adopt this new technology.  
 
First, it is important to consider doctor’s preferences in terms of treatment as they 
influence the type of exams performed. A preference for the tests available will lead 
to a greater acceptance and willingness to use spinit® range of products in GP offices. 
Additionally, as we have seen in the previous subsection, depending on the 
reimbursement policy, doctors can be more willing to invest in new technologies such 
as Biosurfit’s. In this sense, doctors’ preferences are crucial in the choice of a specific 
country, being more probable to select a country to enter into (market selection), 
where doctors are willing to invest in purchasing Biosurfit’s products and give 
preference the available tests. 
 
Regarding patients, their level of aversion to traditional blood tests defines their desire 
to resort to simpler and less painful methods. Additionally, patients need to be willing 
to probably pay an extra amount in order to perform blood tests in the doctor’s office 
instead of going to a central laboratory. The more averse to traditional methods and 
the greater willingness to pay more for a doctor’s appointment will lead to higher 
demand of spinit® products. Hence, patients’ preferences are linked to the acceptance 
of Biosurfit’s products and will consequently lead doctors to acquire them.  
																																																								
14 From the interview with Dr Daniel Neves on 06.12.2017 
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“Not in terms of medical decisions but in terms of personal preferences. If patients 
are or not averse to take blood from the vein or prefer procedure to take blood from a 
finger. If patients are willing or not to pay more for a quick result and not having to 
go to the doctors’ office a second time”15 
 
Market attractiveness resulting from favourable foreign patient and doctor’s 
preferences impacts market selection as Biosurfit chooses the country to expand into 
based on the higher probability of success in that specific country. In fact, the case of 
Biosurfit proves that stakeholders such as foreign governments and customers are 
decisive in order to define an internationalization strategy of the company. 
 
Previous research was done considering the influence of stakeholders upon traditional 
firms (Freeman, 1984; Calof & Beamish, 1995; Mitchell, Agle & Wood, 1997) which 
start by commercializing its products or services within the domestic market and, only 
after achieving a certain level of success, initiate its internationalization to foreign 
markets. Regarding internationalization, those firms follow a step by step, incremental 
process which allows them to gain knowledge and experience in order to 
internationalize successfully. Traditional firms depend on domestic market conditions 
for success, especially on the influence of local regulatory and financial institutions, 
costumers, communities, suppliers among others. Only after being successful in the 
home market will traditional firms expand their operations into foreign markets. In 
this sense, foreign stakeholders are important only as they influence foreign market 
conditions and consequently the success of the company in that new country, they are 
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The purpose of this dissertation is to fill in the gap in the literature regarding the 
influence of foreign stakeholders of the health market in the definition of the 
internationalization strategy of a born global firm.  
Stakeholders are important for every company but the interest of this study is to 
understand their impact specifically on the internationalization strategy of a born 
global firm operating in the health market, which shows different characteristics from 
the other markets. 
 
In order to answer the research question, and fill in the gap found in the literature, we 
used a qualitative approach through a case study method with data collection form 
primary (interviews) and secondary (internal and external documentation) sources. 
We chose as subject to a case study a Portuguese healthcare tech company focusing 
on its internationalization strategy not only for European countries but also to Middle 
Eastern countries. 
 
We have seen and in accordance with the literature, a born global starts selling its 
products abroad, relying on partnerships to obtain success. Besides, we saw that 
stakeholders are crucial to the definition of every firms’ internationalization strategy 
and, after the findings section (chapter 9), we can conclude that governments are 
particularly decisive regarding the internationalization of a company in the health 
sector. Their presence in all activities from the construction of healthcare facilities to 
the definition of Healthcare System and policies make them the principal definer of 
the internationalization strategy of a healthcare tech born global. 
 
In conclusion, despite the importance of all stakeholders, governments have such 
influence upon the health sector that they almost define the strategy used to enter 
international markets.  
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10.2 Limitations & Future research 
 
This dissertation has some limitations that have to be mentioned and may be 
considered for future research purposes. The first limitation arises from the fact that 
we considered the case of one Portuguese born global in the health market. As the 
study was conducted for only one company in a very specific market, the conclusions 
cannot be generalized either for all born global companies neither for all born globals 
operating in the health sector. A second limitation is the fact that there is a deadline 
for the preparation of this thesis of four months and therefore, it is not possible to 
deepen all aspects of the study.  
 
Further research should be conducted in a more extensive way, through qualitative 
and quantitative studies, not only with born globals operating in the health market but 
also with born globals operating in other markets, so that a more general conclusion 
about the influence of foreign stakeholders in the internationalization strategy can be 
made.  
 
Additionally, it is also interesting for further research to investigate if health sector 
operating born globals tend to follow the same strategy of internationalization or 




Appendix 1 – The basic mechanism of internationalization 
 
Source: Adapted from Johanson & Vahlne (1977), page 26 
 
Source: Adapted from Johanson & Vahlne (2009), page 1424 
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Appendix 2 – Company’s stakeholders  
 
Source: Created by the author 2017 
 
Appendix 3 – Relevant situations for different research strategies 
 
Source: Adapted from Yin (2009), page 6 
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Appendix 4 – Interviews conducted 
 
Interviewee Position Date Time Interesting Topics 
Dr João Fonseca CEO 03.11.2017 30 min 
Overall idea of the company: 
- the history; the product; 
internationalization process 
- further interviews 
Dr Daniel Neves CMO & CFO 06.12.2017 30 min 
Overall idea of the company 
Internationalization process: 
- market selection and entry mode; 
stakeholders importance 











06.12.2017 30 min 
Internationalization process 
- market selection and entry mode; 
stakeholders importance; difficulties and 
barriers to internationalization 
- importance of international fairs 
- further expansion 
 










Description of the 
company; Description of 




























Description of the 
company, products, 












Appendix 6 – Data Analysis using coding approach 
 
Topic Author Representative Quotations 
Customers Dr Luis Lopes 
“Arab population like to meet and deal with people face-to-face 
(...) and we saw more progress and achieved more results after 
visiting the country than through months of non-face-to-face 
negotiation.” 
Distributors Dr Daniel Neves 
"We have decided to have an indirect channel of distribution, we 
will not sell directly in each country as our target is GP offices 
and primary care units." 
"The distributor chosen cannot be selling other products with the 
same end use (…) need to be in a situation where they can make 
an initial investment in our (Biosurfit) products." 
Fairs 
Dr Daniel Neves 
"We started by going to the principal international fairs of our 
sector (…) focusing on the discovery distributors of medical 
devices that have interest in selling our product and after maybe 
sign a distribution agreement." 
Dr Luis Lopes 
"The knowledge acquired in fairs enables us to adapt our 
internationalization strategy to each geographical area (…) 
based on the defined approach." 
Dra Sofia Ribeiro 
“At international fairs, we (Biosurfit) talk to many people from 
many different countries and many different types of companies. 
(…) We end up being able to extract some valuable information 
about markets which facilitates the choice of a market to enter in 
and furthermore we end up expanding our already existing 
network. (…) Thus, international fairs are, in fact, a big 
investment made by us (Biosurfit) in terms of 
internationalization.” 
Governments Dr Daniel Neves 
"The minimum requirements in order for us to sell our products 
are CE marking, which allows us to sell within the EU; ISO 9001 
and ISO 13485." 
"Governments decide which blood tests will be included in the 
reimbursement policy (…) also because of the doctors’ 
preferences on deciding each treatment to apply." 
Market 
Dr Daniel Neves 
"Each country has its own market specificities/barriers that 
influence us: National Healthcare System and market access; 
Reimbursement policies and different preferences."  
“Not in terms of medical decisions but in terms of personal 
preferences. If patients are or not averse to take blood from the 
vein or prefer procedure to take blood from finger. If patients are 
willing or not to pay more for a quick result and not having to go 
to the doctors’ office a second time.” 
"We started by BENELUX namely the Netherlands. The 
Netherlands' market was very attractive as it already had a 
reimbursement scheme well defined (…) and a system where 
patients need to first go to a doctors' office and only then to the 
hospital." 
"If the National Healthcare System encourages the realization of 
blood tests near the patient it becomes attractive to us." 
Dr João Fonseca 
"We have followed an approach in which priorities are defined 
taking into account the following elements: Regulatory approvals 
(...) the value of reimbursement, depending on the existence of 
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specific reimbursement for point of care, the level of use of the 
available tests according to preferences and the size of the 
market." 
Dr Luis Lopes 
"In general we (Biosurfit) search for countries with a strong 
point of care market, independently of its size (…) it is also 
important the type of tests preferred in each country." 
"For example we learnt that markets that seem atractive like 
Germany are not atractive to us (Biosurfit) because it doesn't 
have an interesting point of care market (…) markets such as 
Romania became interesting at a pharmacy level." 
Dra Sofia Ribeiro 
"To explain how Biosurfit chooses the markets, we start by 
studying each country to understand how the point of care 
market is. Other important factor is the reimbursement policy 
which can turn atractive or not to commercialization of our 








Source: Adapted from informational email sent by company 20.12.2017 
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Appendix 8 – Number of spinit® machines per country, in October 2017	
 
 
Source: Adapted from informational email sent by company 20.12.2017 
 
  
Countries Nº spinit® % Total spinit®
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